Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Daiichinkyo CoFRA:D4S +1.75%80 Return-on-Tangible-Asset is 4.75% as of Mar. 2026, which is 10% below its 10-year median of 5.26. GuruFocus rates FRA:D4S with a GF Score™ of 80/100 and a GF Value™ of €32.25 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Daiichinkyo Co ranks better than 70.83% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Daiichinkyo Co's annualizedNet Income for the quarter that ended in Mar. 2026 was €925 Mil. Daiichinkyo Co's average total tangible assets for the quarter that ended in Mar. 2026 was €19,486 Mil. Therefore, Daiichinkyo Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 4.75%.
The historical rank and industry rank for Daiichinkyo Co's Return-on-Tangible-Asset or its related term are showing as below:
FRA:D4S'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 3.31 Med: 5.26 Max: 9.39
Current: 7.83
During the past 13 years, Daiichinkyo Co's highest Return-on-Tangible-Asset was 9.39%. The lowest was 3.31%. And the median was 5.26%.
FRA:D4S's Return-on-Tangible-Asset is ranked better than 70.83% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 3.12
vs FRA:D4S: 7.83
Daiichinkyo Co (FRA:D4S) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Daiichinkyo Co Return-on-Tangible-Asset Related Terms
Daiichinkyo Co Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Daiichinkyo Co's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:D4S vs LLY, JNJ, ABBV: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - General subindustry, Daiichinkyo Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Daiichinkyo Co Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Daiichinkyo Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 4.75% mean?
Daiichinkyo Co (FRA:D4S) has a Return-on-Tangible-Asset of 4.75% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Daiichinkyo Co and its competitors. This is 10% below median its historical median of 5.26. Over the past decade, Daiichinkyo Co's Return-on-Tangible-Asset has ranged from 3.31 to 9.39. According to the industry distribution chart, Daiichinkyo Co ranks #294 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 29.2%.
Is Daiichinkyo Co's Return-on-Tangible-Asset too high?
Daiichinkyo Co's current Return-on-Tangible-Asset of 4.75% is 10% below median its 10-year median of 5.26. Over the past 10 years, this metric has ranged from a low of 3.31 to a high of 9.39. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.12. Daiichinkyo Co's value of 4.75% is 52.2% above this industry median. Based on the distribution chart, Daiichinkyo Co ranks #294 out of 1008 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Daiichinkyo Co has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Daiichinkyo Co's Return-on-Tangible-Asset compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Daiichinkyo Co ranks #294 out of 1008 companies for Return-on-Tangible-Asset. This puts Daiichinkyo Co in the upper half of its industry. The industry median Return-on-Tangible-Asset is 3.12. Daiichinkyo Co's value of 4.75% is 52.2% above this benchmark. Historically, Daiichinkyo Co's own Return-on-Tangible-Asset has ranged from 3.31 to 9.39 over the past decade. While the company's 10-year median is 5.26 vs. the industry median of 3.12, Daiichinkyo Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.12, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Daiichinkyo Co's current Return-on-Tangible-Asset of 4.75% is 52.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Daiichinkyo Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Daiichinkyo Co's current Return-on-Tangible-Asset is 4.75%, which is 10% below median its own 10-year median of 5.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Daiichinkyo Co stock overvalued right now?
Based on GuruFocus' analysis, Daiichinkyo Co (FRA:D4S) is currently considered Significantly Undervalued. The stock's GF Value™ is €32.25, compared to a current price of €15.22 — trading 52.8% below its estimated fair value. The current Return-on-Tangible-Asset is 4.75%, which is 10% below median its 10-year median of 5.26 and 52.2% above the Drug Manufacturers industry median of 3.12. Daiichinkyo Co's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Daiichinkyo Co (FRA:D4S), the current Return-on-Tangible-Asset is 4.75% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Daiichinkyo Co (FRA:D4S) Overvalued in 2026?
Based on GuruFocus' analysis, Daiichinkyo Co stock appears to be undervalued.
The current stock price of €15.22 is trading 52.8% below its estimated GF Value™ of €32.25.
GuruFocus considers Daiichinkyo Co to be Significantly Undervalued.
Key valuation signals for FRA:D4S:
Return-on-Tangible-Asset: 4.75% (10% below median its 10-year median of 5.26)
GF Value™: €32.25 vs. price of €15.22 (52.8% below fair value)
Industry Position: 52.2% above the Drug Manufacturers median (#294 of 1008)
No single metric tells the full story. See the FRA:D4S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2024, approximately one quarter of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its lead ADCs are Enhertu (HER2), Datroway (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu was first approved in the US in December 2019, and Datroway was first approved in January 2025.
80GF Score
Get the complete analysis for FRA:D4S
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:D4S has been successfully added to your 
